stoxline Quote Chart Rank Option Currency Glossary
  
Curis, Inc. (CRIS)
10.63  -0.24 (-2.21%)    03-28 11:39
Open: 10.95
High: 10.95
Volume: 6,838
  
Pre. Close: 10.87
Low: 10.4098
Market Cap: 63(M)
Technical analysis
2024-03-28 12:17:03 PM
Short term     
Mid term     
Targets 6-month :  12.92 1-year :  15.09
Resists First :  11.06 Second :  12.92
Pivot price 10.42
Supports First :  9.81 Second :  9.03
MAs MA(5) :  10.64 MA(20) :  10.3
MA(100) :  10.45 MA(250) :  5.02
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  57.7 D(3) :  61.7
RSI RSI(14): 52.8
52-week High :  15.1 Low :  0.37
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CRIS ] has closed below upper band by 31.9%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.89 - 10.94 10.94 - 10.99
Low: 9.96 - 10.02 10.02 - 10.07
Close: 10.78 - 10.87 10.87 - 10.96
Company Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Headline News

Fri, 22 Mar 2024
Citigroup Inc. Has $605,000 Stock Holdings in Curis, Inc. (NASDAQ:CRIS) - MarketBeat

Fri, 22 Mar 2024
Curis, Inc. (NASDAQ:CRIS) Shares Sold by Citigroup Inc. - Defense World

Fri, 09 Feb 2024
Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Fri, 09 Feb 2024
Curis Inc. Is Worried About This – Should You Be Worried Too? - TipRanks.com - TipRanks

Thu, 08 Feb 2024
Curis Provides Fourth Quarter 2023 Business Update - PR Newswire

Thu, 08 Feb 2024
Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 5 (M)
Held by Insiders 0.2 (%)
Held by Institutions 34.8 (%)
Shares Short 56 (K)
Shares Short P.Month 47 (K)
Stock Financials
EPS -8.97
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.33
Profit Margin 0 %
Operating Margin -452.5 %
Return on Assets (ttm) -32.5 %
Return on Equity (ttm) -143.2 %
Qtrly Rev. Growth -6.6 %
Gross Profit (p.s.) 0
Sales Per Share 1.7
EBITDA (p.s.) -8.17
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -1.19
PEG Ratio 0
Price to Book value 3.18
Price to Sales 6.24
Price to Cash Flow -1.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android